Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3903133A (Rabies G SAM) in Healthy Adults
NCT04062669Phase 1Completed
- Sponsor
- GSK
- Start
- Aug 2019
- Primary completion
- Jul 2021
- Modality
- Vaccine mRNA, mRNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK3903133A in rabies (6 arms), sponsored by GSK. Primary endpoints: Number of participants reporting solicited local adverse events, Number of participants reporting solicited general adverse events and 3 more. Started Aug 2019; status: completed.
02
Drugs
GSK3903133A
03
Conditions
rabies
Beyond the preview
Go deeper on NCT04062669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04062669.